High-dose chemotherapy in breast cancer

Drugs

Volumn 64, Issue 17, 2004, Pages 1851-1861

  Lake, Diana E ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; MYELOABLATIVE AGENT; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA;

ADJUVANT CHEMOTHERAPY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AXILLARY LYMPH NODE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MEGADOSE; DRUG RESPONSE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; METASTASIS; PALLIATIVE THERAPY; PNEUMONIA; QUALITY OF LIFE; RELAPSE; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT FAILURE;

EID: 4544378600     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464170-00001     Document Type: Review

References (40)

1. Hudis CA, Munster PN. High-dose therapy for breast cancer. Semin Oncol 1999; 26: 35-47
2. Peters WP, Dansey RD, Klein JL, et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 2000; 5: 1-13
3. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) in node positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332: 901-6
4. Skipper H, Schabel FJ, Wilcox W. Experimental evaluation of potential anticancer agents XIII: on the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Chemother Rep 1964; 35: 1-111
5. Norton L, Simon R, Brereton J, et al. Predicting the course of Gompertzian growth. Nature 1976; 264: 542-5
6. Wood W, Budman D, Korzun A, et al. Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253-9
7. Lotz J, Cure H, Janvier M, et al. High-dose chemotherapy (HDCT) with hemopoietic stem cell transplantation (HSCT) for metastatic breast cancer (MBC): results of the French Protocol PEGASE 04 [abstract]. Proc Am Soc Clin Oncol 1999; 18: 43a
8. Rodenhuis S, Richel D, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet 1998; 352: 515-21
9. Hortobagyi G, Buzdar A, Theriault R, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast cancer. J Natl Cancer Inst 2000; 92: 225-33
10. Peters W, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alklyating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 [abstract]. Proc Am Soc Clin Oncol 1999; 18: 2
11. Scandinavian Breast Cancer Study Group. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy [abstract no. 3]. Proc Am Soc Clin Oncol 1999; 18: 192a
12. Stadtmauer E, O'Neill A, Goldstein L, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem cell transplant group. N Engl J Med 2000; 342 (15): 1069-76
13. Autologous Blood and Marrow Transplant Registry (ABMTR). Distribution and frequencies of autotransplants performed between 1992 and 1997 and registered with the ABMTR. ABMTR Newsletter 1998; 5: 2
14. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43
15. Weiss R, Gill G, Hudis C. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol 2001; 19: 2771-7
16. van Amerongen D. Insurance payments for bone marrow transplantation in metastatic breast cancer [letter]. N Engl J Med 2000; 342: 1138-9
17. Rodenhuis S. The status of high-dose chemotherapy in breast cancer. Oncologist 2000; 5: 369-75
18. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-42
19. Laughlin MJ, McGaughey DS, Crews JR, et al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 1998; 16: 1008-12
20. Curtis RE, Boice JDJ, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745-51
21. Rodenhuis S. High-dose chemotherapy in breast cancer: interpretation of the randomized trials. Anticancer Drugs 2001; 12: 85-8
22. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 Study. Lancet 2000; 356: 1384-91
23. Budman D, Berry D, Cirrincione C, et al. Dose and dose intensity as determinants of outcome in the adjvuant treatment of breast cancer. J Natl Cancer Inst 1998; 90: 1205-11
24. Thor A, Berry D, Budman D, et al. erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-60
25. Rodenhuis S, Bontenbal M, Beex L, et al. Randomized phase III study of high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes [abstract]. Proc Am Soc Clin Oncol 2000; 19: 74a
26. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16
27. Crown J, Lind M, Gould A, et al. High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+LN): the Anglo-Celtic I study [abstract]. Proc Am Soc Clin Oncol 2002; 21: 12a
28. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17-26
29. Stadtmauer E, O'Neill A, Goldstein L, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem-cell transplantation (SCT) for metastatic breast cancer: 5-year update of the 'Philadelphia Trial' (PBT-1) [abstract]. Proc Am Soc Clin Oncol 2002; 21: 43a
30. Peters W, Jones R, Vredenburgh J, et al. A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 121
31. Peters W, Jones RB, Vredenburgh J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction (AFM) [abstract no. 11]. Breast Cancer Res Treat 1995; 37: 35
32. Biron P, Durand M, Roche H, et al. High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer: results of the PEGASE 03 French Protocol [abstract]. Proc Am Soc Clin Oncol 2002; 21: 167
33. Lotz JP, Devaux Y, Extra JM, et al. Autologous bone marrow transplantation (ABMT) after high-dose cyclophosphamide, mitoxantrone, alkeran (CMA) in breast cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12: A160
34. Schmid P, Schippinger S, Nitsch T, et al. Up front tandem high-dose chemotherapy compared to standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: updated results of a randomized trial [abstract]. Breast Cancer Res Treat 2003; 82: S152
35. Maden B, Broadwater G, Rubin P, et al. Improved survival with consolidation high dose cyclophosphamide, cisplatin and carmustine (HD-CPB) compared with observation in women with metastatic breast cancer (MBC) and only bone metastases treated with induction Adriamycin, 5-fluorouracil and methotrexate (AFM): a phase III prospective randomized comparative trial [abstract]. Proc Am Soc Clin Oncol 2000; 19: 48a
36. Schmid P, Samonigg H, Nitsch T, et al. Randomized trial of up front tandem high-dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 2002; 21: 43a
37. Berry D, Broadwater G, Klein J, et al. High dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the autologous blood and marrow transplant Registry. J Clin Oncol 2002; 20: 743-50
38. Crown J, Leyvraz S, Perey L, et al. Superiority of tandem high-dose chemotherapy over conventionally dosed chemotherapy in unselected patients with metastatic breast cancer: the International Randomized Breast Cancer Dose Intensity Study [abstract]. Breast Cancer Res Treat 2003; 82: S152
39. Rizzieri DA, Vredenburgh JJ, Jones R, et al. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999; 17: 3064-74
40. Citron ML, Berry D, Cirrincione C, et al. Superiority of dose-dense over conventional scheduling and equivalence of sequential (SC) vs combination adjuvant chemotherapy (CC) for node positive breast cancer (CALGB9741 INTC9741) [abstract no. 15]. Breast Cancer Res Treat 2002; 76 Suppl. I